Overview

Olmesartan Pediatric Pharmacokinetic (PK) Study

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Determine single dose pharmacokinetic parameters of olmesartan in pediatric patients with hypertension in ages 12 months - 16 years
Phase:
Phase 1
Details
Lead Sponsor:
Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.
Treatments:
Olmesartan
Olmesartan Medoxomil